The biotech CMOs winning in 2026 are not the ones with the biggest teams. They're the ones who rebuilt their stack around AI agents, structured data, and tight feedback loops between marketing, BD, and clinical.
What "AI-first" actually means in regulated industries
It does not mean shipping a chatbot on your homepage. It means: every brief, every asset, every campaign passes through an AI workflow that drafts, fact-checks against your own scientific corpus, and routes for human medical/legal/regulatory review. The human is the editor, not the typist.
The three workflows worth automating first
- Competitive and KOL intelligence. Daily scans of clinicaltrials.gov, PubMed, and SEC filings, summarized into a single morning brief.
- Sales enablement. Account-specific one-pagers generated from your CRM data and the prospect's pipeline, ready for the AE before the call.
- SEO and content velocity. Topic clusters built from real keyword data, drafted by AI, reviewed by your scientific team, published weekly instead of quarterly.
Why San Diego is uniquely positioned
The density of biotech, AI talent at UCSD and the Salk Institute, and a maturing generative-AI startup scene downtown makes San Diego the easiest U.S. city to staff an AI-first biotech marketing function. The fractional model lets you tap that talent without building a full in-house AI team on day one.